What does Locus Cell Co., Ltd. do?

Locus Cell Co., Ltd. (6891.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6891.TWO's market cap?

Locus Cell Co., Ltd. (6891.TWO) has a market capitalization of approximately $8.62 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6891.TWO pay a dividend?

No — Locus Cell Co., Ltd. (6891.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6891.TWO profitable?

Locus Cell Co., Ltd. (6891.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6891.TWO

Locus Cell Co., Ltd.

TWO·Biotechnology · Healthcare

NT$43.00NT$1.90+4.62%

Market capNT$8.62B·Aug 26 6:59 AM UTC

Price Chart

NT$43.00+NT$1.90 (+4.62%)today

−12.96%CAGR −3.15%

Select date range

FromTo

Apr 28, 2022Apr 28, 2022 → Aug 26, 2026· 4.3 yrsAug 26, 2026

Key Metrics

6891.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

Income Statement Flow

PRO

See exactly how 6891.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6891.TWO and 80,000+ other tickers.

About Locus Cell Co., Ltd.

Locus Cell Co., Ltd. is a specialist in the biotechnology and cell therapy sector. The company primarily offers contract development and manufacturing (CDMO) services for a variety of cellular products. This includes handling diverse cell types such as adipose-derived stem cells, nerve cells, chondrocytes, and fibroblasts. Furthermore, their capabilities extend to advanced manufacturing processes like 3D bioprinting for cellular constructs. Locus Cell also provides CDMO support for cutting-edge regenerative medical products, including therapies based on CAR-T, mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs).

CEO: Yu Hsiang Chang
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 53
Website: www.locus-cell.com

Peers

Peers Tab

4157.TWO

TaiGen Biopharmaceuticals Holdings Limited

Cap

NT$6.5B

6875.TWO

Pharmosa Biopharm Inc.

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6891.TWO

What does Locus Cell Co., Ltd. do?: Locus Cell Co., Ltd. (6891.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6891.TWO's market cap?: Locus Cell Co., Ltd. (6891.TWO) has a market capitalization of approximately $8.62 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6891.TWO pay a dividend?: No — Locus Cell Co., Ltd. (6891.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6891.TWO profitable?: Locus Cell Co., Ltd. (6891.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.